SOURCE: Zenosense, Inc.

Zenosense, Inc.

September 17, 2014 08:33 ET

Zenosense, Inc. Update -- MRSA and Lung Cancer Device Development

VALENCIA, SPAIN--(Marketwired - Sep 17, 2014) - Zenosense, Inc. (OTCQB: ZENO) ("Zenosense," the "Company"), a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA "Super-Bug" and to detect signs of lung cancer in exhaled breath, is pleased to provide an update on its device development status.

Development operations are proceeding as planned, with recent achievements summarized as:


A new sensor design has been defined for manufacturing which includes a new MRSA/SA VOC (Volatile Organic Compound) biomarker micro-separator technology and tests have been initiated to measure and contrast cultures of MRSA and SA.

Electronics design for a microbiology lab device is complete, and industrial design for the device is in process. The electronics and new sensor are expected to be integrated in the coming weeks to produce the first prototype for laboratory detection of MRSA/SA in cultures.

Lung Cancer ("LC")

First tests using a LC VOC biomarker selected from existing hospital research data have been carried out. Good sensitivity to this VOC biomarker using the current sensor has been obtained, the VOC biomarker typically being expressed by LC patients at levels well within the capability of the sensor. Further tests will be carried out with the intention of resolving issues with cross-sensitivity with other VOC biomarkers and other ambient compounds. A review of literature and current research is in hand with alternative VOC biomarkers identified.

A device for clinical tests with lung cancer patients has been designed, including electronics and a VOC capturing system. This device is intended to meet hospital clinical procedure requirements.

About Zenosense, Inc.

Zenosense, Inc. is a detection device development company based in Valencia, Spain. Its mission is to develop effective medical devices targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients and market and sell these products to hospitals and primary healthcare facilities. Two devices are currently under development; a device intended to detect the Methicillin-resistant Staphylococcus aureus "Super-Bug" (MRSA); and a device intended to detect Lung Cancer. Using a common Electronic Nose technology platform, the devices analyze Volatile Organic Compounds (VOCs) which are present in the exhaled breath of patients, scanning for certain biomarkers which can indicate the presence of infection/illness.

Find out more at

Forward-Looking Statements

Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013 filed on filed on March 26, 2014, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Statements concerning the development of both the MRSA device and the lung cancer device have been made based on information obtained from Zenon Biosystem, which the Company believes to be accurate, but have not been independently verified.

Contact Information